P-1 along with the dendritic and myeloid cells it attracts are elevated within the mSOD1 mouse model of ALS. Mol Cell Neurosci 2006, 31:427?37. 21. Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, et al: Immune method alterations in sporadic amyotrophic lateral sclerosis sufferers suggest an ongoing neuroinflammatory approach. J Neuroimmunol 2009, 210:73?9. 22. Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Lancero M, Narvaez A, McGrath MS: MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2006, 179:87?three. 23. Dawson J, Miltz W, Mir AK, Wiessner C: Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets 2003, 7:35?8. 24. Roebuck KA, Carpenter LR, Lakshminarayanan V, Page SM, Moy JN, Thomas LL: Stimulus-specific regulation of chemokine expression includes differential activation from the redox-responsive transcription elements AP-1 and NF-B. J Leukoc Biol 1999, 65:291?98.2-Chloro-5,7-difluorobenzo[d]thiazole Order 25. Allavena P, Bianchi G, Zhou D, van Damme J, J ek P, Sozzani S, Mantovani A: Induction of organic killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994, 24:3233?236. 26. Amantea D, Nappi G, Bernardi G, Bagetta G, Corasaniti MT: Post-ischemic brain damage: pathophysiology and function of inflammatory mediators. FEBS J 2009, 276:13?6. 27. Hinojosa AE, Garcia-Bueno B, Leza JC, Madrigal JL: CCL2/MCP-1 modulation of microglial activation and proliferation. J Neuroinflammation 2011, 8:77. 28. Lee EO, Park HJ, Kang JL, Kim HS, Chong YH: Resveratrol reduces glutamate-mediated monocyte chemotactic protein-1 expression by means of inhibition of extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures. J Neurochem 2010, 112:1477?487. 29. Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivis k P, Tucky B, et al: Modulating CCR2 and CCL2 in the blood rain barrier: relevance for a number of sclerosis pathogenesis. Brain 2006, 129:212?23. 30. Semple BD, Bye N, Rancan M, Ziebell JM, Morganti-Kossmann MC: Part of CCL2 (MCP-1) in traumatic brain injury (TBI): proof from severe TBI sufferers and CCL2-/- mice. J Cereb Blood Flow Metab 2010, 30:769?82.31. Tanabe S, Heesen M, Berman MA, Fischer MB, Yoshizawa I, Luo Y, Dorf ME: Murine astrocytes express a functional chemokine receptor. J Neurosci 1997, 17:6522?528. 32. Kuhle J, Lindberg RL, Regeniter A, Mehling M, Steck AJ, Kappos L, Czaplinski A: Improved levels of inflammatory chemokines in amyotrophic lateral sclerosis.Methyl acetyl-L-cysteinate Data Sheet Eur J Neurol 2009, 16:771?74.PMID:33480405 33. Philips T, Robberecht W: Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron illness. Lancet Neurol 2011, 10:253?63. 34. Tateishi T, Yamasaki R, Tanaka M, Matsushita T, Kikuchi H, Isobe N, Ohyagi Y, Kira J: CSF chemokine alterations associated to the clinical course of amyotrophic lateral sclerosis. J uroimmunol 2010, 222:76?1. 35. Coughlan CM, McManus CM, Sharron M, Gao Z, Murphy D, Jaffer S, et al: Expression of a number of functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience 2000, 97:591?00. 36. Meng SZ, Oka A, Takashima S: Developmental expressison of monocyte chemoattractant protein-1 within the human cerebellum and brainstem. Brain Dev 1999, 21:30?five. 37. Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyanf G, et al: Modulating inflammatory monocytes with a distinctive microRNA gene signature ameliorates murine ALS. J Clin In.
